Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response
Lauren S. Levine(Cancer Research Institute), Matthew H. Spitzer(Unknown), Kamir J. Hiam-Galvez(University of California, San Francisco), Iliana Tenvooren(University of California, San Francisco), Olalekan O. Oluwole(Vanderbilt University), Jonathan M. Irish(Vanderbilt University), Debolanle O. Dahunsi(Vanderbilt University Medical Center), Jeffrey C. Rathmell(University of Chicago), Diana M. Marquez(Stanford University), Diana C. Contreras(Vanderbilt University Medical Center), Matthew Z. Madden(Emory University)
Cited by 128
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
|The Journal of Immunology|2011|2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Systemic immunity in cancer
|Nature reviews. Cancer|2021|1.3k